Pharmatrexate 50mg IV/IM Inj. 1`s

A healthcare professional administers this injection under close medical supervision.

Pharmatrexate 50mg IV/IM Injection Ingredients and Usage

Pharmatrexate 50mg IV/IM Injection contains methotrexate, an antimetabolite belonging to the folic acid antagonist drug class. Oncologists prescribe it for leukemia, lymphoma, osteosarcoma, and cancers affecting the uterus, breast, or meninges.

Rheumatologists and dermatologists also use Pharmatrexate 50mg IV/IM Injection for severe rheumatoid arthritis and psoriasis that has not responded to oral therapy or other treatments. A specialist determines the route, dose, and schedule based on the specific condition being treated.

How Does Pharmatrexate 50mg IV/IM Injection Work?

Methotrexate inhibits dihydrofolate reductase, an enzyme that converts dihydrofolate into tetrahydrofolate. Tetrahydrofolate is required to synthesize purines and pyrimidines, the building blocks of DNA and RNA.

By blocking this pathway, Pharmatrexate 50mg IV/IM Injection halts the proliferation of rapidly dividing cells, including cancer cells and the immune cells driving joint and skin inflammation. Intramuscular injection produces effects within 30 to 60 minutes, faster than oral dosing.

Pharmatrexate 50mg IV/IM Injection Side Effects

Pharmatrexate 50mg IV/IM Injection commonly causes digestive and general side effects, which tend to be more pronounced at higher oncology doses.

• Nausea and vomiting

• Diarrhea

• Mouth sores

• Fatigue

• Injection site irritation

• Hair thinning

• Headache

Warnings

• Pharmatrexate 50mg IV/IM Injection is strictly contraindicated in pregnancy and breastfeeding, since it can cause severe fetal harm.

• The medicine can cause serious bone marrow suppression, so regular complete blood counts are required throughout treatment.

• Avoid use in patients with severe liver or kidney impairment; baseline liver function tests are needed before starting therapy.

• Pharmatrexate 50mg IV/IM Injection can cause severe lung injury, including pulmonary fibrosis; report new cough or breathlessness immediately.

• Do not use in patients with active infection, significant bone marrow suppression, or active peptic ulcer disease and gastrointestinal bleeding.

• Avoid alcohol during treatment, since it increases the risk of liver toxicity when combined with methotrexate.

• Elderly patients face higher toxicity risk due to reduced kidney function, so doctors should use extra caution when dosing this group.

Pharmatrexate 50mg IV/IM Injection Storage Conditions

Store Pharmatrexate 50mg IV/IM Injection refrigerated between 2°C and 8°C, and do not freeze the vial. Protect the vial from light and keep it in its original carton until use. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.